VRTX insider buying and SEC filings, explained
Vertex Pharmaceuticals Inc. / MA · CIK 875320
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- MA
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$158.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jul 2, 2026 | Planned (10b5-1) | Ourania Tatsis (EVP, Chief Reg. & Quality Off.) sold 1,500 shares at $524.99 ($787K), marked as a 10b5-1 plan trade. Holdings down 3% to 45,321 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 2, 2026 | Planned (10b5-1) | Duncan McKechnie (EVP, Chief Commercial Officer) sold 1,541 shares at $519.00 ($800K), marked as a 10b5-1 plan trade. Holdings down 12% to 11,001 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Joy Liu (EVP and Chief Legal Officer) sold 828 shares at $502.71 ($416K), marked as a 10b5-1 plan trade. Holdings down 4% to 19,131 shares. | SEC filing Filed Jul 6, 2026 |
| Jun 26, 2026 | Planned (10b5-1) | Carmen Bozic (EVP and CMO) sold 596 shares at $482.50 ($288K), marked as a 10b5-1 plan trade. Holdings down 4% to 15,337 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 18, 2026 | Planned (10b5-1) | Carmen Bozic (EVP and CMO) sold 1,020 shares at $462.17 ($471K), marked as a 10b5-1 plan trade. Holdings down 6% to 15,933 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Carmen Bozic (EVP and CMO) sold 4,062 shares at $450.00 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 19% to 16,953 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 5, 2026 | Planned (10b5-1) | Carmen Bozic (EVP and CMO) sold 1,745 shares at $450.00 ($785K), marked as a 10b5-1 plan trade. Holdings down 8% to 21,015 shares. | SEC filing Filed Jun 9, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Joy Liu (EVP and Chief Legal Officer) sold 828 shares at $439.91 ($364K), marked as a 10b5-1 plan trade. Holdings down 4% to 19,959 shares. | SEC filing Filed Jun 3, 2026 |
| May 29, 2026 | Planned (10b5-1) | Carmen Bozic (EVP and CMO) sold 1,974 shares at $450.00 ($888K), marked as a 10b5-1 plan trade. Holdings down 8% to 22,760 shares. | SEC filing Filed Jun 2, 2026 |
| May 15, 2026 | Planned (10b5-1) | Mark E. Bunnage (EVP, Chief Scientific Officer) sold 33 shares at $453.45 ($15K), marked as a 10b5-1 plan trade. Holdings down <1% to 7,284 shares. | SEC filing Filed May 19, 2026 |
| May 15, 2026 | Planned (10b5-1) | Carmen Bozic (EVP and CMO) sold 1,354 shares at $453.45 ($614K), marked as a 10b5-1 plan trade. Holdings down 5% to 24,734 shares. | SEC filing Filed May 19, 2026 |
| May 12, 2026 | Planned (10b5-1) | Carmen Bozic (EVP and CMO) sold 6,988 shares at $450.00 ($3.1M), marked as a 10b5-1 plan trade. Holdings down 21% to 26,088 shares. | SEC filing Filed May 14, 2026 |
| May 1, 2026 | Planned (10b5-1) | Joy Liu (EVP and Chief Legal Officer) sold 1,104 shares at $425.02 ($469K), marked as a 10b5-1 plan trade. Holdings down 5% to 20,729 shares. | SEC filing Filed May 5, 2026 |
| May 4, 2026 | Planned (10b5-1) | Sangeeta N. Bhatia (Director) sold 318 shares at $423.73 ($135K), marked as a 10b5-1 plan trade. Holdings down 6% to 4,924 shares. | SEC filing Filed May 5, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Joy Liu (EVP and Chief Legal Officer) sold 978 shares at $449.17 ($439K), marked as a 10b5-1 plan trade. Holdings down 4% to 21,833 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 27, 2026 | Planned (10b5-1) | Carmen Bozic (EVP and CMO) sold 2,329 shares at $450.95 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 7% to 33,076 shares. | SEC filing Filed Mar 31, 2026 |
| Mar 13, 2026 | Planned (10b5-1) | Carmen Bozic (EVP and CMO) sold 2,329 shares at $481.79 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 6% to 35,405 shares. | SEC filing Filed Mar 17, 2026 |
| Mar 11, 2026 | Planned (10b5-1) | Duncan McKechnie (EVP, Chief Commercial Officer) sold 2,633 shares at $498.42 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 17% to 12,489 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 4, 2026 | Planned (10b5-1) | Duncan McKechnie (EVP, Chief Commercial Officer) sold 2,437 shares at $475.30 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 14% to 15,122 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Joy Liu (EVP and Chief Legal Officer) sold 892 shares at $495.96 ($442K), marked as a 10b5-1 plan trade. Holdings down 4% to 22,811 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 27, 2026 | Planned (10b5-1) | Reshma Kewalramani (CEO and Director) sold 40,000 shares at about $493.47 ($19.7M), marked as a 10b5-1 plan trade. Holdings down 29% to 98,278 shares. | SEC filing Filed Mar 3, 2026 |
| Feb 27, 2026 | Planned (10b5-1) | Carmen Bozic (EVP and CMO) sold 2,329 shares at $480.31 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 6% to 37,734 shares. | SEC filing Filed Mar 3, 2026 |
| Feb 26, 2026 | Planned (10b5-1) | Kristen Ambrose (SVP & Chief Accounting Officer) sold 357 shares at $483.36 ($173K), marked as a 10b5-1 plan trade. Holdings down 5% to 6,624 shares. | SEC filing Filed Mar 2, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Ourania Tatsis (EVP, Chief Reg. & Quality Off.) sold 260 shares at $486.35 ($126K), marked as a 10b5-1 plan trade. Holdings down 1% to 46,763 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Amit Sachdev (EVP Chief Patient & Ext Af Off) sold 1,846 shares at $486.35 ($898K), marked as a 10b5-1 plan trade. Holdings down 3% to 55,570 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Duncan McKechnie (EVP, Chief Commercial Officer) sold 4,910 shares at about $487.65 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 22% to 17,559 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Mark E. Bunnage (EVP, Chief Scientific Officer) sold 620 shares at $486.35 ($302K), marked as a 10b5-1 plan trade. Holdings down 8% to 7,284 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Jonathan Biller (EVP and Chief Legal Officer) sold 945 shares at $486.35 ($460K), marked as a 10b5-1 plan trade. Holdings down 6% to 13,659 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Edward Morrow Atkinson III (EVP, Chief Technical Ops. Off.) sold 668 shares at $486.35 ($325K), marked as a 10b5-1 plan trade. Holdings down 3% to 18,432 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Kristen Ambrose (SVP & Chief Accounting Officer) sold 223 shares at $486.35 ($108K), marked as a 10b5-1 plan trade. Holdings down 3% to 6,981 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 19, 2026 | Planned (10b5-1) | Amit Sachdev (EVP Chief Patient & Ext Af Off) sold 58,613 shares at about $468.83 ($27.5M), marked as a 10b5-1 plan trade. Holdings down 50% to 58,934 shares. | SEC filing Filed Feb 23, 2026 |
| Feb 17–18, 2026 | Planned (10b5-1) | Ourania Tatsis (EVP, Chief Reg. & Quality Off.) sold 977 shares between Feb 17 and Feb 18 at about $483.52 ($472K), marked as a 10b5-1 plan trade. Holdings down 2% to 48,650 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 17–18, 2026 | Planned (10b5-1) | Mark E. Bunnage (EVP, Chief Scientific Officer) sold 3,619 shares between Feb 17 and Feb 18 at about $484.31 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 30% to 8,486 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 17–18, 2026 | Planned (10b5-1) | Jonathan Biller (EVP and Chief Legal Officer) sold 3,720 shares between Feb 17 and Feb 18 at about $484.18 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 19% to 15,748 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 17–18, 2026 | Planned (10b5-1) | Edward Morrow Atkinson III (EVP, Chief Technical Ops. Off.) sold 2,848 shares between Feb 17 and Feb 18 at about $484.93 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 12% to 20,727 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 17–18, 2026 | Planned (10b5-1) | Kristen Ambrose (SVP & Chief Accounting Officer) sold 2,195 shares between Feb 17 and Feb 18 at about $484.87 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 22% to 7,750 shares. | SEC filing Filed Feb 19, 2026 |
| Feb 13, 2026 | Planned (10b5-1) | Ourania Tatsis (EVP, Chief Reg. & Quality Off.) sold 1,500 shares at about $499.99 ($750K), marked as a 10b5-1 plan trade. Holdings down 3% to 46,132 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 13, 2026 | Planned (10b5-1) | Jonathan Biller (EVP and Chief Legal Officer) sold 988 shares at $499.00 ($493K), marked as a 10b5-1 plan trade. Holdings down 6% to 16,838 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 13, 2026 | Planned (10b5-1) | Sangeeta N. Bhatia (Director) sold 266 shares at $500.00 ($133K), marked as a 10b5-1 plan trade. Holdings down 6% to 4,299 shares. | SEC filing Filed Feb 18, 2026 |
| Feb 11, 2026 | Planned (10b5-1) | Ourania Tatsis (EVP, Chief Reg. & Quality Off.) sold 466 shares at $460.43 ($215K), marked as a 10b5-1 plan trade. Holdings down 1% to 51,436 shares. | SEC filing Filed Feb 12, 2026 |
| Feb 11, 2026 | Planned (10b5-1) | Mark E. Bunnage (EVP, Chief Scientific Officer) sold 2,021 shares at $460.43 ($931K), marked as a 10b5-1 plan trade. Holdings down 14% to 12,914 shares. | SEC filing Filed Feb 12, 2026 |
| Feb 11, 2026 | Planned (10b5-1) | Jonathan Biller (EVP and Chief Legal Officer) sold 1,925 shares at $460.43 ($886K), marked as a 10b5-1 plan trade. Holdings down 8% to 20,819 shares. | SEC filing Filed Feb 12, 2026 |
| Feb 11, 2026 | Planned (10b5-1) | Edward Morrow Atkinson III (EVP, Chief Technical Ops. Off.) sold 1,751 shares at $460.43 ($806K), marked as a 10b5-1 plan trade. Holdings down 7% to 22,046 shares. | SEC filing Filed Feb 12, 2026 |
| Feb 11, 2026 | Planned (10b5-1) | Kristen Ambrose (SVP & Chief Accounting Officer) sold 1,376 shares at $460.43 ($634K), marked as a 10b5-1 plan trade. Holdings down 12% to 10,127 shares. | SEC filing Filed Feb 12, 2026 |
| Jan 7, 2026 | Planned (10b5-1) | Ourania Tatsis (EVP, Chief Reg. & Quality Off.) sold 4,500 shares at $474.99 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 10% to 42,293 shares. | SEC filing Filed Jan 9, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Charles F. Wagner Jr. (EVP, Co & Fo) sold 9,532 shares at $461.00 ($4.4M), marked as a 10b5-1 plan trade. Holdings down 20% to 37,725 shares. | SEC filing Filed Jan 8, 2026 |
| Dec 3, 2025 | Planned (10b5-1) | Charles F. Wagner Jr. (EVP, Co & Fo) sold 14,000 shares at about $456.00 ($6.4M), marked as a 10b5-1 plan trade. Holdings down 27% to 37,725 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | Ourania Tatsis (EVP, Chief Reg. & Quality Off.) sold 4,500 shares at about $449.99 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 9% to 46,793 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | Jeffrey M. Leiden (Chair and Director) sold 63,781 shares at about $449.20 ($28.7M), marked as a 10b5-1 plan trade. Holdings down 73% to 24,026 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | Jonathan Biller (EVP and Chief Legal Officer) sold 347 shares at $449.00 ($156K), marked as a 10b5-1 plan trade. Holdings down 2% to 15,306 shares. | SEC filing Filed Dec 5, 2025 |
| Nov 17, 2025 | Planned (10b5-1) | Edward Morrow Atkinson III (EVP, Chief Technical Ops. Off.) sold 2,500 shares at $434.58 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 13% to 16,852 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 13–14, 2025 | Planned (10b5-1) | Jeffrey M. Leiden (Chair and Director) sold 73,292 shares between Nov 13, 2025 and Nov 14, 2025 at about $440.60 ($32.3M), marked as a 10b5-1 plan trade. Holdings down 75% to 24,026 shares. | SEC filing Filed Nov 17, 2025 |
82 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 4:05 PM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow VRTX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.